康辰药业
(603590)
| 流通市值：39.34亿 | | | 总市值：39.90亿 |
| 流通股本：1.58亿 | | | 总股本：1.60亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 646,310,729.73 | 405,024,853.01 | 199,236,548.72 | 920,011,779.75 |
| 营业收入 | 646,310,729.73 | 405,024,853.01 | 199,236,548.72 | 920,011,779.75 |
| 二、营业总成本 | 518,431,065.74 | 317,146,155.19 | 150,670,966.09 | 773,683,870.38 |
| 营业成本 | 68,708,878.94 | 42,387,416.16 | 22,456,553.78 | 101,049,346.68 |
| 税金及附加 | 5,190,277.67 | 3,455,661 | 1,333,618.9 | 5,901,821.18 |
| 销售费用 | 322,345,827.07 | 193,746,682.98 | 90,449,693.33 | 472,585,019.74 |
| 管理费用 | 89,275,691.13 | 56,522,302.28 | 26,163,429.01 | 110,695,900.76 |
| 研发费用 | 35,041,400.54 | 23,294,981.62 | 11,319,522.81 | 94,911,121.7 |
| 财务费用 | -2,131,009.61 | -2,260,888.85 | -1,051,851.74 | -11,459,339.68 |
| 其中:利息费用 | 4,375,208.79 | 2,637,685.12 | 1,233,405.67 | 2,781,312.72 |
| 其中:利息收入 | 9,559,067.6 | 6,359,917.75 | 2,922,648.08 | 13,770,166.78 |
| 加:公允价值变动收益 | 1,599,401.32 | 923,478.38 | 1,047,983.04 | -866,800.61 |
| 加:投资收益 | 12,201,416.52 | 10,109,565.73 | -536,926.37 | 5,561,216.99 |
| 资产处置收益 | -7,331.58 | - | - | -8,228.93 |
| 资产减值损失(新) | - | - | - | -11,911,117.24 |
| 信用减值损失(新) | -585,167.98 | -180,061.9 | -4,220.55 | -7,252,203.95 |
| 其他收益 | 3,313,438.42 | 2,201,276.16 | 1,189,922.57 | 11,432,343.27 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 144,401,420.69 | 100,932,956.19 | 50,262,341.32 | 143,283,118.9 |
| 加:营业外收入 | 1,335.25 | 978.72 | 444.93 | 261,495.64 |
| 减:营业外支出 | 190,501.27 | 129,648.52 | 26.66 | 20,811,458.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 144,212,254.67 | 100,804,286.39 | 50,262,759.59 | 122,733,156.2 |
| 减:所得税费用 | 20,688,703.01 | 13,523,270.03 | 3,417,662.73 | -64,838,548.76 |
| 六、净利润 | 123,523,551.66 | 87,281,016.36 | 46,845,096.86 | 187,571,704.96 |
| 持续经营净利润 | 123,523,551.66 | 87,281,016.36 | 46,845,096.86 | 187,571,704.96 |
| 归属于母公司股东的净利润 | 112,975,682.11 | 79,202,846.22 | 41,654,332.06 | 150,450,744.29 |
| 少数股东损益 | 10,547,869.55 | 8,078,170.14 | 5,190,764.8 | 37,120,960.67 |
| (一)基本每股收益 | 0.72 | 0.5 | 0.27 | 0.96 |
| (二)稀释每股收益 | 0.72 | 0.5 | 0.27 | 0.96 |
| 八、其他综合收益 | 51,595,510.65 | 18,880,650.61 | 38,109,331.65 | 6,298,661.26 |
| 归属于母公司股东的其他综合收益 | 51,595,510.65 | 18,880,650.61 | 38,109,331.65 | 6,298,661.26 |
| 九、综合收益总额 | 175,119,062.31 | 106,161,666.97 | 84,954,428.51 | 193,870,366.22 |
| 归属于母公司股东的综合收益总额 | 164,571,192.76 | 98,083,496.83 | 79,763,663.71 | 156,749,405.55 |
| 归属于少数股东的综合收益总额 | 10,547,869.55 | 8,078,170.14 | 5,190,764.8 | 37,120,960.67 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |